>Ankylosing spondylitis (AS) is a chronic inflammatory disorder of the spine and the area where the spine connects to the pelvis (known as the sacroiliac joints). Sacroiliac joint involvement is considered the hallmark of this disorder and is a requirement for diagnosis.
Ankylosing spondylitis is categorized as a seronegative spondyloarthropathy. The term seronegative means that a blood test result does not show the presence of rheumatoid arthritis, and the term spondyloarthropathy means a disease that affects the joints of the spine. These inflammatory disorders affect multiple systems of the body. Other disorders in this category include: Reiter syndrome (reactive arthritis); arthritis associated with inflammatory bowel disease, such as Crohn disease and ulcerative colitis; psoriatic arthritis; undifferentiated spondyloarthropathies; juvenile chronic arthritis; and juvenile-onset ankylosing spondylitis.
Ankylosing spondylitis affects approximately 0.1-0.2% of the world population and is more prevalent in individuals of Northern European ancestry. People with ankylosing spondylitis often have a family member with the disease or one of the other spondyloarthropathy disorders listed above.
| Printer-Friendly Format | | | Email to a Friend |
Get the latest treatment options
Cymbalta is approved for the treatment of fibromyalgia.
Important Safety Information
Cymbalta® (duloxetine HCl) is approved for the treatment of depression and generalized anxiety disorder, and for the management of diabetic peripheral neuropathic pain and fibromyalgia.
Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, unusual changes in behavior, thoughts of suicide, anxiety, agitation, panic attacks, difficulty sleeping, irritability, hostility, aggressiveness, impulsivity, restlessness, or extreme hyperactivity. Call your healthcare provider right away if you have thoughts of suicide or if any of these symptoms are severe or occur suddenly. Be especially observant within the first few months of antidepressant treatment or whenever there is a change in dose.
You should not take Cymbalta if:
Before starting Cymbalta, tell your healthcare provider:
While taking Cymbalta, tell your healthcare provider:
If you have any questions, talk to your healthcare provider before taking Cymbalta.
The most common side effect of Cymbalta was nausea. For most people who had it, the nausea was mild to moderate. Other common side effects included dry mouth, sleepiness, constipation, decreased appetite, and, increased sweating. This is not a complete list of side effects.
Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder of the sacroiliac (SI) joints and the axial skeleton.
|